PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30116283-3 2018 The small-molecule NAD+ mimetics, olaparib, niraparib, rucaparib, veliparib, and talazoparib, inhibit the catalytic activity of PARP-1 and PARP-2 and are currently being studied in later-stage clinical trials. olaparib 34-42 poly(ADP-ribose) polymerase 2 Homo sapiens 139-145 29262611-5 2017 PARP1 and PARP2 depletion suppressed the phenotype while PARP2 overexpression enhanced it, suggesting that olaparib-bound PARP1 and PARP2 rather than the lack of catalytic activity causes this phenotype. olaparib 107-115 poly(ADP-ribose) polymerase 2 Homo sapiens 57-62 29262611-5 2017 PARP1 and PARP2 depletion suppressed the phenotype while PARP2 overexpression enhanced it, suggesting that olaparib-bound PARP1 and PARP2 rather than the lack of catalytic activity causes this phenotype. olaparib 107-115 poly(ADP-ribose) polymerase 2 Homo sapiens 10-15 29262611-5 2017 PARP1 and PARP2 depletion suppressed the phenotype while PARP2 overexpression enhanced it, suggesting that olaparib-bound PARP1 and PARP2 rather than the lack of catalytic activity causes this phenotype. olaparib 107-115 poly(ADP-ribose) polymerase 2 Homo sapiens 57-62 29262611-6 2017 Olaparib-induced mitotic chromatid scattering was observed in various cancer cell lines with increased protein levels of PARP1 and PARP2, but not in non-cancer or cancer cell lines that expressed lower levels of PARP1 or PARP2. olaparib 0-8 poly(ADP-ribose) polymerase 2 Homo sapiens 131-136 29262611-6 2017 Olaparib-induced mitotic chromatid scattering was observed in various cancer cell lines with increased protein levels of PARP1 and PARP2, but not in non-cancer or cancer cell lines that expressed lower levels of PARP1 or PARP2. olaparib 0-8 poly(ADP-ribose) polymerase 2 Homo sapiens 221-226 29262611-7 2017 Interestingly, the sister chromatid scattering phenotype occurred only when olaparib was added during the S-phase preceding mitosis, suggesting that PARP1 and PARP2 entrapment at replication forks impairs sister chromatid cohesion. olaparib 76-84 poly(ADP-ribose) polymerase 2 Homo sapiens 159-164 25757679-0 2015 Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer. olaparib 0-8 poly(ADP-ribose) polymerase 2 Homo sapiens 29-35 26931795-2 2016 Olaparib, a potent PARP1 and PARP2 inhibitor, has been shown to significantly increase progression-free survival (PFS) in women with recurrent ovarian cancer related to a germline BRCA mutation and is currently approved fourth-line treatment in these patients. olaparib 0-8 poly(ADP-ribose) polymerase 2 Homo sapiens 29-34 25757679-1 2015 Olaparib (Lynparza ; AZD2281) is a potent PARP-1 and PARP-2 inhibitor with biologic activity in ovarian cancer as well as other solid tumors. olaparib 0-8 poly(ADP-ribose) polymerase 2 Homo sapiens 53-59 25757679-1 2015 Olaparib (Lynparza ; AZD2281) is a potent PARP-1 and PARP-2 inhibitor with biologic activity in ovarian cancer as well as other solid tumors. olaparib 10-18 poly(ADP-ribose) polymerase 2 Homo sapiens 53-59 25757679-1 2015 Olaparib (Lynparza ; AZD2281) is a potent PARP-1 and PARP-2 inhibitor with biologic activity in ovarian cancer as well as other solid tumors. olaparib 21-28 poly(ADP-ribose) polymerase 2 Homo sapiens 53-59 34880209-3 2021 Mechanistic studies show that Olaparib causes adaptive resistance by arresting the cell cycle at S and G2/M phases for HR repair, increasing the expression of CDK6, CCND1, CDK1, CCNA1, CCNB1, and CDC25B to promote cell cycle progression, and inducing the overexpression of FOXM1, PARP1/2, BRCA1/2, and Rad51 to activate precise repair of damaged DNA. olaparib 30-38 poly(ADP-ribose) polymerase 2 Homo sapiens 280-287 18800822-4 2008 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2 H-phthalazin-1-one (KU-0059436, AZD2281) 47 is a single digit nanomolar inhibitor of both PARP-1 and PARP-2 that shows standalone activity against BRCA1-deficient breast cancer cell lines. olaparib 89-99 poly(ADP-ribose) polymerase 2 Homo sapiens 170-176 22524618-3 2012 Olaparib is an orally bioavailable inhibitor of PARP-1 and PARP-2 that has been tested in multiple clinical trials. olaparib 0-8 poly(ADP-ribose) polymerase 2 Homo sapiens 59-65 34880209-4 2021 FDI-6 inhibits the expression of FOXM1, PARP1/2, and genes involved in cell cycle control and DNA damage repair to sensitize TNBC cells to Olaparib by blocking cell cycle progression and DNA damage repair. olaparib 139-147 poly(ADP-ribose) polymerase 2 Homo sapiens 40-47 35349716-8 2022 In PARP1-deficient cells, PARP inhibitors - niraparib, talazoparib, and, to a lesser extent, olaparib - enhance PARP2 foci by preventing PARP2 exchange. olaparib 93-101 poly(ADP-ribose) polymerase 2 Homo sapiens 112-117 35349716-8 2022 In PARP1-deficient cells, PARP inhibitors - niraparib, talazoparib, and, to a lesser extent, olaparib - enhance PARP2 foci by preventing PARP2 exchange. olaparib 93-101 poly(ADP-ribose) polymerase 2 Homo sapiens 137-142 32221289-1 2020 PARP1 and PARP2 dual inhibitors, such as olaparib, have been recently FDA approved for the treatment of advanced breast and ovarian cancers. olaparib 41-49 poly(ADP-ribose) polymerase 2 Homo sapiens 10-15 32221289-3 2020 Here we show that olaparib increases breast cancer bone metastasis through PARP2, but not PARP1, specifically in the myeloid lineage, but not in the cancer cells. olaparib 18-26 poly(ADP-ribose) polymerase 2 Homo sapiens 75-80 34461785-3 2021 The most potent compound (PARP1/2 IC50 = 22/4.0 nM) displayed the highest selectivity towards PARP2 in the series (selectivity index = 5.5), more advantageous ADME prameters compared to the clinically used PARP inhibitor Olaparib. olaparib 221-229 poly(ADP-ribose) polymerase 2 Homo sapiens 94-99 35430559-4 2022 Herein, we describe a novel PROTACs C8, which was obtained by conjugating PARP1/2 inhibitor Olaparib to KB02, can induce potent and specific degradation of PARP2 by recruiting DCAF16 E3 ligase for treatment of wild-type TNBC. olaparib 92-100 poly(ADP-ribose) polymerase 2 Homo sapiens 156-161 33637776-10 2021 BKM120 downregulated the expression of PARP1 and PARP2 to assist olaparib in blocking PARP mediated repair of DNA SSBs. olaparib 65-73 poly(ADP-ribose) polymerase 2 Homo sapiens 49-54